Lipoprotein(a) metabolism: potential sites for therapeutic targets. - Wikidata - wikimedia - TriplyDB

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

http://www.wikidata.org/entity/Q36539756

about

Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role Low levels of blood lipids are associated with etiology and lethal outcome in acute liver failure Hepatitis B virus inhibits apolipoprotein A5 expression through its core gene Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis).Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study.Lipoprotein (a): impact by ethnicity and environmental and medical conditions Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.Lipoprotein(a): a not-so-well-known risk factor for the development of cardiovascular disease in patients with type 2 diabetes mellitus Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement.Positive association between serum apolipoprotein M levels and hepatitis B virus DNA load in HBeAg-negative chronic hepatitis B.Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients.PCSK9 targets important for lipid metabolism Lp(a)/apo(a) modulate MMP-9 activation and neutrophil cytokines in vivo in inflammation to regulate leukocyte recruitment.New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?Lipoprotein(a) as a therapeutic target in cardiovascular disease.Targeting lipoprotein (a): an evolving therapeutic landscape.The metabolism of lipoprotein (a): an ever-evolving story.Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention.Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related Macular Degeneration.Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.Improvement of hepatic bioavailability as a new step for the future of statin.Lipoprotein(a)-clinical aspects and future challenges Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options.The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD.Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.Lipoprotein(a) concentrations in adult congenital heart disease patients.Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients.miR-23b-3p and miR-125b-5p downregulate apo(a) expression by targeting Ets1 in HepG2 cells.Low LPA gene kringle IV-2 repeat copy number association with elevated lipoprotein (a) concentration as an independent risk factor of coronary atherosclerotic heart disease in the Chinese Han population.

P2860

Q26747100-7D438990-3889-4DD8-B335-5ED3004F7FEE Q28540768-C3151CF9-732B-49A4-BBA8-53716FEEBBF7 Q28597775-06BF02EC-D12B-45B1-A0DC-F9949E0DFA44 Q34458693-437EF9B8-1B88-4433-B7DD-C010D83E5B7E Q35130714-E1AC9A86-0AE5-4F06-81E4-B5B7078E75D9 Q35789087-DFC763B2-E685-497B-AA41-4C8F827B68C7 Q36148940-9E43CFA7-B399-4C10-9826-FA7B0174BFF2 Q36696683-4365EB94-D99D-452A-93E3-F70E4F978D3D Q36731797-E576EEC8-271D-4641-9984-DFED0C7B1346 Q37033161-EDDEB8D9-BFFF-4E76-84DC-C50A69D4E6BC Q37163064-61D63699-DDD1-4983-82B0-5E6844F27742 Q37285933-61DC1791-7C9B-49EB-8D6C-8EF1E5925BEF Q37392497-1E0D1016-7073-4ABD-A526-48C3C7C7DD6D Q37400701-B2EB9332-E7E3-44E0-A1D4-F165B81CCBF0 Q37481056-94AA178A-AB90-483D-8F19-1F119E0D23A6 Q37636912-B349C3B4-DC64-43FD-A12F-E2DC061CF2F1 Q37676748-A6357951-62AD-4D48-BC4B-DD3D07F39E33 Q37703261-431B1364-15FE-409F-A561-90F7D40FF5E4 Q37734908-C572E6A5-60CF-4EAF-A69E-B966F4A5E052 Q38126418-042BB847-40CA-429F-A728-4443A21D3391 Q38213476-C151FDD3-40DE-4605-94C8-A590E6B7BBBA Q38367355-E9994723-A699-473F-BD7B-20E870D9F9DE Q38655614-25E5881D-BB17-4601-9A8C-1278A46452D1 Q38727796-77EC58A5-DFE7-49DF-958A-71564DD9D9DD Q38752767-F24A36ED-3591-473E-83EB-F745F47A05B5 Q38818826-ABB6EDEA-D91B-40FD-AF8C-01B51815F6FB Q38839105-661A1FDD-5C29-4BCA-A1A6-D3EB79F55A4B Q38915148-402CE6A3-22E4-47CE-9850-8D180997B874 Q38925742-1E651636-7E6F-4976-B9CE-BA16B81C58AA Q38985774-4677808F-9376-4BDD-A900-7DD8649D48D7 Q39004218-42B0A8B5-6EFD-4D2E-920A-F0365002BD4A Q39033744-1501E906-B2F4-4698-A855-44E785B406B5 Q39054740-46B8433F-C9F3-4BAA-AB34-792C81DCF468 Q39197341-0BE1B539-62CE-48CC-8611-A8CF417AC7F9 Q40757066-1951F278-ABB6-4BD7-9AD9-A2F2F3F0D44F Q46048138-2660F029-9CC3-44DA-A5CB-A5A65ED85213 Q46239308-B4C6B739-A1C9-4B92-93F0-63A09D0CB25B Q50075849-A73E07DE-2959-4FB6-B5E6-207F4B5953DA Q55253271-C6F15BE3-2196-45DD-9A29-9BB0D1A77078

P2860

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

http://www.wikidata.org/entity/Q36539756

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

@ast

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

@en

type

label

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

@ast

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

@en

prefLabel

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

@ast

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

@en

P1433

Q36539756-5BC68277-7969-4B91-A675-1C833C4FDA7D

P1476

Q36539756-63506B9B-57C4-4AE3-9645-A01F130DD628

P2093

Q36539756-A9D96933-D933-4BDB-A597-DBBE3E05DCEF

Q36539756-B5661A01-9AA9-4C27-8764-CCEDB217C968

P2860

Q36539756-00EBB31E-5C4E-4C7B-B021-D36AA513F03A

Q36539756-03323A0A-56A0-46F9-AC53-8CAC7E6441BE

Q36539756-048D3FD5-1749-4D8F-856E-9D241209B7FD

Q36539756-066E1D5D-184D-4D36-85B1-FF80C7A55BD9

Q36539756-06EEDED3-6527-4C4C-9A03-16FFAD8DFBA1

Q36539756-0814B55B-1A39-4375-BCC9-76E014AC9378

Q36539756-0D906AF7-3151-41FA-9511-F58EC88E47B1

Q36539756-0F7AB263-9AF5-4B37-9281-4E961255CE9E

Q36539756-1466653E-7A4D-4683-BDE6-6A80B284BA2B

Q36539756-19AB275A-4FC6-460B-81A2-2F2629053527

P304

Q36539756-F2EDDCEA-999A-4ECD-88D0-589FEA021969

P31

Q36539756-7C52397B-678B-41AE-A474-5C9D69793A72

P356

Q36539756-ECAD2B52-6481-4FD2-9576-14062E57EADF

P433

Q36539756-6151F883-27F6-4885-A032-9324C6352E4D

P478

Q36539756-CC2AA9D9-CCA8-4929-9D4D-EA91E94140C5

P577

Q36539756-D3F16B16-8BEB-4ED4-8776-D8B02AF04732

P698

Q36539756-8D2C1061-D4E1-48B3-B9A6-242A3E64E5DF

P921

Q36539756-81AAA86C-1DE8-4F31-B27B-821D004F6F58

Q36539756-C9E3BF15-EAAB-49B0-8434-D74AC23CADE0

P932

Q36539756-B2F952E5-0B0E-4099-B530-D2DD4A591577

P356

J.METABOL.2012.07.024

P1433

P1476

Lipoprotein(a) metabolism: potential sites for therapeutic targets.

@en

P2093

Jane Hoover-Plow

http://www.w3.org/2001/XMLSchema#string

Menggui Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Lipoprotein(a) as a cardiovascular risk factor: current status

Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro

Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)

Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology

A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM

Direct interaction of the extracellular matrix protein DANCE with apolipoprotein(a) mediated by the kringle IV-type 2 domain

The Kringle V-protease domain is a fibrinogen binding region within Apo(a)

Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study

Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments

Lipoprotein(a): current perspectives

P304

479-491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.METABOL.2012.07.024

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23040268

http://www.w3.org/2001/XMLSchema#string

P921

P932

3547132

http://www.w3.org/2001/XMLSchema#string